Izrael - hebrejščina - Ministry of Health

sanofi - aventis israel ltd - coagulation factor ix (recombinant fc fusion protein –rfixfc) - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ix (recombinant fc fusion protein –rfixfc) 1000 iu - coagulation factor ix

Izrael - hebrejščina - Ministry of Health

sanofi - aventis israel ltd - coagulation factor ix (recombinant fc fusion protein –rfixfc) - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ix (recombinant fc fusion protein –rfixfc) 2000 iu - coagulation factor ix

Izrael - hebrejščina - Ministry of Health

sanofi - aventis israel ltd - coagulation factor ix (recombinant fc fusion protein –rfixfc) - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ix (recombinant fc fusion protein –rfixfc) 3000 iu - coagulation factor ix

Izrael - hebrejščina - Ministry of Health

sanofi - aventis israel ltd - coagulation factor ix (recombinant fc fusion protein –rfixfc) - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ix (recombinant fc fusion protein –rfixfc) 500 iu - coagulation factor ix

Izrael - hebrejščina - Ministry of Health

csl behring ltd., israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein c; protein s antigen - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ii (human) 400 - 960 iu; coagulation factor vii (human) 200 - 500 iu; coagulation factor ix (human- rfixfc) 400 - 620 iu; coagulation factor x (human) 440 - 1200 iu; protein c 300 - 900 iu; protein s antigen 240 - 760 iu - coagulation factor ix, ii, vii and x in combination

Izrael - hebrejščina - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; hepatitis b vaccines; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus protein conjugate; tetanus toxoid - תרחיף להזרקה - diphtheria toxoid; tetanus protein conjugate 22 - 36 mcg / 0.5 ml; haemophilus influenzae type b polysaccharide 12 mcg / 0.5 ml; hepatitis b vaccines 10 mcg / 0.5 ml; poliovirus type 3 inactivated 32 du / 0.5 ml; poliovirus type 2 inactivated 8 du / 0.5 ml; poliovirus type 1 inactivated 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus-hepatitis b

Izrael - hebrejščina - Ministry of Health

kamada ltd, israel - cytomegalovirus antibody; human plasma protein; immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 96 %; human plasma protein 50 mg/ml; cytomegalovirus antibody 100 u/ml - cytomegalovirus immunoglobulin

Izrael - hebrejščina - Ministry of Health

sanofi israel ltd - conjugated to tetanus protein; diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; pertussis toxoid (pt); polio type i (mohoney); polio type ii ( m.e.f.1); polio type iii (saukett); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - polio type iii (saukett) 32 du / 0.5 ml; polio type ii ( m.e.f.1) 8 du / 0.5 ml; polio type i (mohoney) 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid 40 iu / 0.5 ml; diphtheria toxoid 30 iu / 0.5 ml; haemophilus influenzae type b polysaccharide 10 mcg / 0.5 ml; conjugated to tetanus protein 18-30 mcg / 0.5 ml - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

Izrael - hebrejščina - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

Izrael - hebrejščina - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii